Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 25, 2017 - Issue 3
Submit an article Journal homepage
368
Views
15
CrossRef citations to date
0
Altmetric
Articles

Infliximab after Boston Keratoprosthesis in Stevens–Johnson Syndrome: An Update

Marie-Claude RobertDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD,
Alja ČrnejDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD,
Lucy Q. ShenDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD,
George N. PapaliodisDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD,
Reza DanaDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD, MPH, MSc,
C. Stephen FosterMassachusetts Eye Research & Surgery Institute, Waltham, Massachusetts, USA
, MD,
James ChodoshDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USA
, MD, MPH &
Claes H. DohlmanDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts, USACorrespondence[email protected]
, MD, PhD show all
Pages 413-417 | Received 05 Jul 2015, Accepted 13 Jan 2016, Published online: 25 Mar 2016

REFERENCES

  • Dohlman C, Cruzat A, White M. The Boston keratoprosthesis 2014: a step in the evolution of artificial corneas. Spektrum Augenheilkd. 2014;28:226–233.
  • Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20:19–23.
  • Dohlman C, Dudenhoefer E, Khan B, et al. Corneal blindness from end-stage Sjögren’s syndrome and graft-versus-host disease. In: Sullivan D, Stern M, Tsubota K, et al. eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. New York: Kluwer/Plenum; 2002:1335–1338.
  • Dohlman J, Foster C, Dohlman CH. Boston Keratoprosthesis in Stevens–Johnson syndrome: A case of using infliximab to prevent tissue necrosis. Digit J Ophthalmol. 2009;15:1–2.
  • Ciralsky J, Papaliodis G, Foster C, et al. Keratoprosthesis in autoimmune disease. Ocul Immunol Inflamm. 2010;18:275–280.
  • Pham M, Chow CC, Badawi D, et al. Use of Infliximab in the Treatment of Peripheral Ulcerative Keratitis in Crohn Disease. Am J Ophthalmol. 2011;152:183–188.e2.
  • Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. Cornea. 2005;24:742–744.
  • Odorcic S, Keystone EC, Ma JJK. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea. 2009;28:89–92.
  • Antao SF, Ayoub T, Tahir H, et al. Stabilization of bilateral progressive rheumatoid corneal melt with infliximab. Case Rep Ophthalmol Med. 2012;2012:1–3.
  • Ferrari G, Bignami F, Giacomini C, et al. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci. 2013; 54:1680–1688.
  • Qian Y, Dekaris I, Yamagami S, et al. Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants. Arch Ophthalmol. 2000; 118:1666.
  • Li Z, Choi W, Oh H-J, et al. Effectiveness of topical infliximab in a mouse model of experimental dry eye. Cornea. 2012;31 Suppl 1:S25–S31.
  • Sayegh RR, Ang LPK, Foster CS, et al. The Boston keratoprosthesis in Stevens–Johnson syndrome. Am J Ophthalmol. 2008;145:438–444.
  • Alikhani M, Alikhani Z, Raptis M, et al. TNF-alpha in vivo stimulates apoptosis in fibroblasts through capsase-8 activation and modulates the expression of pro-apoptotic genes. J Cell Physiol. 2004;201:341–348.
  • Beauregard C, Hug SO, Barabino S, et al. Keratocyte apoptosis and failure of corneal allografts. Transplantation. 2006;81:1577–1582.
  • Coassin M, Zhang C, Green W, et al. Histopathologic and immunologic aspects of alphacor artificial corneal failure. Am J Ophthalmol. 2007;144:699–704.
  • Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014; 121:1877–1884.
  • Schaap-Fogler M, Amer R, Friling R, et al. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:633–640.
  • Robert M, Spurr-Michaud S, Frenette M, et al. Stability and in vitro toxicity of an infliximab eye drop formulation. Int J Pharm Compd. 2014;18:418–426.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.